1️⃣ Datroway moved first in TNBC FDA approved AstraZeneca and Daiichi Sankyo’s Datroway for first-line metastatic triple-negative breast cancer patients who are not candidates for PD-1/PD-L1 therapy.
💡 Why it matters This gives Dato-DXd the first FDA-cleared TROP2 ADC slot in a front-line TNBC niche before Gilead’s Trodelvy can answer there.
☕ Coffee talk How long does that first-line TNBC lead stay clean once Gilead has to defend Trodelvy outside the salvage setting?
2️⃣ Hepcludex finally crossed FDA’s line FDA approved Gilead’s Hepcludex for chronic hepatitis delta infection, the first US-approved treatment for HDV, under accelerated approval.
💡 Why it matters Gilead turns the MYR buyout into a US rare-liver label after years of Europe-first access and an earlier FDA setback.
☕ Coffee talk After the CRL and the Europe delay, does Hepcludex still look like a rare-disease asset or a clean-up job?
3️⃣ Medtronic bought earlier pain intervention Medtronic agreed to acquire SPR Therapeutics for about US$650m upfront, adding the FDA-cleared 60-day SPRINT peripheral nerve stimulation system.
💡 Why it matters This is not a moonshot deal: Medtronic is buying a reimbursed, non-opioid pain procedure to widen its neuromodulation funnel.
☕ Coffee talk If 60-day stimulation works before permanent implants, what happens to the old pain-device ladder?